CO6311066A2 - Composiciones de alta densidad que contienen posaconazol y formulaciones que comprenden las mismas - Google Patents
Composiciones de alta densidad que contienen posaconazol y formulaciones que comprenden las mismasInfo
- Publication number
- CO6311066A2 CO6311066A2 CO10141841A CO10141841A CO6311066A2 CO 6311066 A2 CO6311066 A2 CO 6311066A2 CO 10141841 A CO10141841 A CO 10141841A CO 10141841 A CO10141841 A CO 10141841A CO 6311066 A2 CO6311066 A2 CO 6311066A2
- Authority
- CO
- Colombia
- Prior art keywords
- posaconazole
- formulation
- oral administration
- provides
- patients
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 10
- RAGOYPUPXAKGKH-XAKZXMRKSA-N posaconazole Chemical compound O=C1N([C@H]([C@H](C)O)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@H]3C[C@@](CN4N=CN=C4)(OC3)C=3C(=CC(F)=CC=3)F)=CC=2)C=C1 RAGOYPUPXAKGKH-XAKZXMRKSA-N 0.000 title abstract 9
- 229960001589 posaconazole Drugs 0.000 title abstract 9
- 238000009472 formulation Methods 0.000 abstract 6
- 230000036470 plasma concentration Effects 0.000 abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 210000002784 stomach Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Inorganic Chemistry (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4517708P | 2008-04-15 | 2008-04-15 | |
| US16648709P | 2009-04-03 | 2009-04-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6311066A2 true CO6311066A2 (es) | 2011-08-22 |
Family
ID=41199703
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO10141841A CO6311066A2 (es) | 2008-04-15 | 2010-11-11 | Composiciones de alta densidad que contienen posaconazol y formulaciones que comprenden las mismas |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20110123627A1 (enExample) |
| EP (1) | EP2285351A2 (enExample) |
| JP (3) | JP2011516612A (enExample) |
| KR (1) | KR20110004852A (enExample) |
| CN (2) | CN102065842A (enExample) |
| AR (1) | AR072858A1 (enExample) |
| AU (1) | AU2009236289B2 (enExample) |
| BR (1) | BRPI0910627A2 (enExample) |
| CA (1) | CA2720849A1 (enExample) |
| CL (1) | CL2009000902A1 (enExample) |
| CO (1) | CO6311066A2 (enExample) |
| MX (1) | MX2010011295A (enExample) |
| NZ (1) | NZ588460A (enExample) |
| PE (1) | PE20091778A1 (enExample) |
| PH (1) | PH12015500492A1 (enExample) |
| SG (1) | SG10201403986UA (enExample) |
| TW (1) | TWI388324B (enExample) |
| WO (1) | WO2009129300A2 (enExample) |
| ZA (1) | ZA201007370B (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2278957A2 (en) * | 2008-04-15 | 2011-02-02 | Schering Corporation | Oral pharmaceutical compositions in a solid dispersion comprising preferably posaconazole and hpmcas |
| EP2540318B1 (en) * | 2010-02-22 | 2018-10-24 | Daiichi Sankyo Company, Limited | Sustained-release solid preparation for oral use |
| KR102228157B1 (ko) * | 2013-06-03 | 2021-03-17 | 신에쓰 가가꾸 고교 가부시끼가이샤 | 가열 용융 압출용 조성물 및 이것을 사용한 가열 용융 압출 성형물의 제조 방법 |
| EP2837391B1 (en) | 2013-08-12 | 2017-05-10 | Shin-Etsu Chemical Co., Ltd. | Hypromellose acetate succinate for use as hot-melt extrusion carrier, hot-melt extrusion composition, and method for producing hot-melt extrudate |
| CN104510707A (zh) * | 2013-09-26 | 2015-04-15 | 博瑞生物医药技术(苏州)有限公司 | 一种泊沙康唑固体分散体及其制备方法 |
| CN104546667A (zh) * | 2013-10-22 | 2015-04-29 | 博瑞生物医药技术(苏州)有限公司 | 含泊沙康唑的固体分散体及其制备方法 |
| CN104721827A (zh) * | 2013-12-18 | 2015-06-24 | 博瑞生物医药技术(苏州)有限公司 | 一种难溶性抗真菌药物固体分散体及其制备方法 |
| CN112022818A (zh) | 2014-02-05 | 2020-12-04 | 默沙东公司 | Cgrp-活性化合物的片剂制剂 |
| CN110179801B (zh) * | 2014-04-11 | 2021-08-06 | 上海宣泰医药科技股份有限公司 | 泊沙康唑药物组合物及其制备方法和药物制剂 |
| WO2017025292A1 (en) | 2015-08-08 | 2017-02-16 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Gastro-resistant formulation containing posaconazole |
| EP4424308A3 (en) | 2016-02-26 | 2024-12-04 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Gastro-resistant formulation containing posaconazole and a polymeric precipitation inhibitor |
| WO2017032908A1 (en) | 2016-07-08 | 2017-03-02 | Synthon B.V. | Pharmaceutical composition comprising amorphous posaconazole |
| CN106265526A (zh) * | 2016-09-22 | 2017-01-04 | 山东大学 | 一种抗真菌药物泊沙康唑的固体分散体及制备方法与应用 |
| TR201620462A2 (tr) | 2016-12-31 | 2018-07-23 | Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi | POSAKONAZOL İÇEREN FARMASÖTİK BİLEŞİMLER ve ÜRETİM YÖNTEMİ |
| US20180282527A1 (en) | 2017-03-30 | 2018-10-04 | Shin-Etsu Chemical Co., Ltd. | Injection molding composition containing hypromellose acetate succinate and method for producing same |
| WO2020159562A1 (en) * | 2019-01-29 | 2020-08-06 | Slayback Pharma Llc | Pharmaceutical compositions of posaconazole |
| WO2021205473A1 (en) * | 2020-04-06 | 2021-10-14 | Bendale Yogesh | Structurally defined, better tolerated, orally adminstered, processed arsenolite, a process for its preparation, a pharmaceutical composition and uses thereof |
| WO2022034232A1 (en) | 2020-08-13 | 2022-02-17 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Gastro-resistant high-strength formulation containing posaconazole |
| CN112697937A (zh) * | 2020-12-18 | 2021-04-23 | 卓和药业集团有限公司 | 泊沙康唑肠溶片溶出度的分析方法 |
| EP4091604B1 (en) | 2021-11-25 | 2024-04-03 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Granules containing posaconazole |
| US20240390363A1 (en) | 2021-11-25 | 2024-11-28 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Granules containing posaconazole |
| CN114184721A (zh) * | 2021-12-14 | 2022-03-15 | 江苏恒盛药业有限公司 | 泊沙康唑残留溶剂的检测方法 |
| CN115721601A (zh) * | 2022-11-23 | 2023-03-03 | 无锡福祈制药有限公司 | 一种泊沙康唑纳米晶口服固体药物组合物及其制备方法 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4144346A (en) * | 1977-01-31 | 1979-03-13 | Janssen Pharmaceutica N.V. | Novel 1-(1,3-dioxolan-2-ylmethyl)-1H-imidazoles |
| SE7804231L (sv) * | 1978-04-14 | 1979-10-15 | Haessle Ab | Magsyrasekretionsmedel |
| US4978672A (en) * | 1986-03-07 | 1990-12-18 | Ciba-Geigy Corporation | Alpha-heterocyclc substituted tolunitriles |
| US4916134A (en) * | 1987-03-25 | 1990-04-10 | Janssen Pharmacuetica N.V. | 4-[4-[4-[4-[[2-(2,4-difluorophenyl)-2-(1H-azolylmethyl)-1,3-dioxolan-4-yl]me]phenyl]-1-piperazinyl]phenyl]triazolones |
| GB8908250D0 (en) * | 1989-04-12 | 1989-05-24 | Fisons Plc | Formulations |
| US5278175A (en) * | 1990-02-02 | 1994-01-11 | Pfizer Inc. | Triazole antifungal agents |
| US5661151A (en) * | 1993-12-21 | 1997-08-26 | Schering Corporation | Tetrahydrofuran antifungals |
| US5703079A (en) * | 1993-12-21 | 1997-12-30 | Schering Corporation | Tetrahydrofuran antifungals |
| NZ270418A (en) * | 1994-02-07 | 1997-09-22 | Eisai Co Ltd | Polycyclic triazole & imidazole derivatives, antifungal compositions |
| GB9602080D0 (en) * | 1996-02-02 | 1996-04-03 | Pfizer Ltd | Pharmaceutical compounds |
| DE69726729T2 (de) * | 1996-05-20 | 2004-12-02 | Janssen Pharmaceutica N.V. | Fungizide mittel mit verbesserter bioverfügbarkeit |
| US5834472A (en) * | 1996-05-24 | 1998-11-10 | Schering Corporation | Antifungal composition with enhanced bioavailability |
| US5972381A (en) * | 1996-06-28 | 1999-10-26 | Schering Corporation | Solid solution of an antifungal agent with enhanced bioavailability |
| US5846971A (en) * | 1996-06-28 | 1998-12-08 | Schering Corporation | Oral antifungal composition |
| US6713481B1 (en) * | 1997-10-17 | 2004-03-30 | David R. Andrews | Crystalline antifungal polymorph |
| CA2396380C (en) * | 1999-12-23 | 2015-04-21 | David Hayes | Improved pharmaceutical compositions for poorly soluble drugs |
| US20010053791A1 (en) * | 2000-03-16 | 2001-12-20 | Babcock Walter C. | Glycogen phosphorylase inhibitor |
| EP1372394A1 (en) * | 2001-04-03 | 2004-01-02 | Schering Corporation | Antifungal composition with enhanced bioavailability |
| WO2003077827A1 (en) * | 2002-03-19 | 2003-09-25 | Nippon Shinyaku Co., Ltd. | Process for producing drug solid dispersion |
| US20050043251A1 (en) * | 2003-08-20 | 2005-02-24 | Fairfield Clinical Trials, Llc | Method of treatment of otitis externa |
| US20060160823A1 (en) * | 2004-05-28 | 2006-07-20 | Leonore Witchey-Lakshmanan | Particulate-stabilized injectable pharmaceutical compositions of Posaconazole |
| US20060062848A1 (en) * | 2004-09-17 | 2006-03-23 | Nektar Therapeutics Uk Limited | Formulation comprising itraconazole |
| US20060275230A1 (en) * | 2004-12-10 | 2006-12-07 | Frank Kochinke | Compositions and methods for treating conditions of the nail unit |
| WO2007056205A2 (en) * | 2005-11-04 | 2007-05-18 | Eastman Chemical Company | Carboxyalkylcellulose esters for administration of poorly soluble pharmaceutically active agents |
| BRPI0712130A2 (pt) * | 2006-05-30 | 2012-01-17 | Elan Pharma Int Ltd | formulações de posaconazol em nanopartìculas |
| JP2010526848A (ja) * | 2007-05-11 | 2010-08-05 | エフ．ホフマン−ラ ロシュ アーゲー | 難溶性薬物用の医薬組成物 |
| EP2278957A2 (en) * | 2008-04-15 | 2011-02-02 | Schering Corporation | Oral pharmaceutical compositions in a solid dispersion comprising preferably posaconazole and hpmcas |
-
2009
- 2009-04-15 PE PE2009000520A patent/PE20091778A1/es active IP Right Grant
- 2009-04-15 EP EP09732010A patent/EP2285351A2/en not_active Withdrawn
- 2009-04-15 BR BRPI0910627A patent/BRPI0910627A2/pt not_active IP Right Cessation
- 2009-04-15 TW TW098112539A patent/TWI388324B/zh active
- 2009-04-15 SG SG10201403986UA patent/SG10201403986UA/en unknown
- 2009-04-15 US US12/999,547 patent/US20110123627A1/en not_active Abandoned
- 2009-04-15 CN CN2009801224878A patent/CN102065842A/zh active Pending
- 2009-04-15 NZ NZ588460A patent/NZ588460A/en unknown
- 2009-04-15 AU AU2009236289A patent/AU2009236289B2/en not_active Expired - Fee Related
- 2009-04-15 CA CA2720849A patent/CA2720849A1/en not_active Abandoned
- 2009-04-15 AR ARP090101320A patent/AR072858A1/es unknown
- 2009-04-15 CN CN201510421108.2A patent/CN104983701A/zh active Pending
- 2009-04-15 WO PCT/US2009/040652 patent/WO2009129300A2/en not_active Ceased
- 2009-04-15 KR KR1020107023010A patent/KR20110004852A/ko not_active Ceased
- 2009-04-15 CL CL2009000902A patent/CL2009000902A1/es unknown
- 2009-04-15 MX MX2010011295A patent/MX2010011295A/es active IP Right Grant
- 2009-04-15 JP JP2011505163A patent/JP2011516612A/ja not_active Ceased
-
2010
- 2010-10-14 ZA ZA2010/07370A patent/ZA201007370B/en unknown
- 2010-11-11 CO CO10141841A patent/CO6311066A2/es not_active Application Discontinuation
-
2014
- 2014-04-02 JP JP2014075980A patent/JP2014139230A/ja active Pending
- 2014-11-24 US US14/551,903 patent/US20150150990A1/en not_active Abandoned
-
2015
- 2015-03-06 PH PH12015500492A patent/PH12015500492A1/en unknown
- 2015-11-24 JP JP2015228422A patent/JP2016074698A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0910627A2 (pt) | 2015-09-22 |
| ZA201007370B (en) | 2011-06-29 |
| CN104983701A (zh) | 2015-10-21 |
| JP2016074698A (ja) | 2016-05-12 |
| KR20110004852A (ko) | 2011-01-14 |
| EP2285351A2 (en) | 2011-02-23 |
| WO2009129300A2 (en) | 2009-10-22 |
| JP2011516612A (ja) | 2011-05-26 |
| CL2009000902A1 (es) | 2010-07-23 |
| MX2010011295A (es) | 2010-11-12 |
| AU2009236289A1 (en) | 2009-10-22 |
| WO2009129300A3 (en) | 2010-02-11 |
| NZ588460A (en) | 2012-07-27 |
| PE20091778A1 (es) | 2009-11-13 |
| JP2014139230A (ja) | 2014-07-31 |
| AU2009236289B2 (en) | 2014-08-21 |
| US20150150990A1 (en) | 2015-06-04 |
| TW200946121A (en) | 2009-11-16 |
| TWI388324B (zh) | 2013-03-11 |
| SG10201403986UA (en) | 2014-10-30 |
| US20110123627A1 (en) | 2011-05-26 |
| CA2720849A1 (en) | 2009-10-22 |
| CN102065842A (zh) | 2011-05-18 |
| PH12015500492A1 (en) | 2017-04-10 |
| AR072858A1 (es) | 2010-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6311066A2 (es) | Composiciones de alta densidad que contienen posaconazol y formulaciones que comprenden las mismas | |
| ES2557475T3 (es) | Un portador que comprende uno o más derivados di- y/o monofosfato de agentes de transferencia de electrones | |
| ES2292643T3 (es) | Tratamiento de los efectos colaterales de la estatina. | |
| ES2846776T3 (es) | Dosificación específica del sitio de un inhibidor de BTK | |
| CY1116874T1 (el) | Δοσολογικο σχημα για τη χορηγηση ενος cd19xcd3 αμφιειδικου αντισωματος | |
| ES2830447T3 (es) | Método para la prevención y/o el tratamiento del deterioro cognitivo asociado al envejecimiento y la neuroinflamación | |
| BR122023020985A2 (pt) | Formulação de comprimido sólido de um inibidor de tirosina quinase de bruton | |
| AT501681A1 (de) | Organische verbindungen | |
| ES2899226T3 (es) | Composiciones liofilizadas en superficie específica elevada que comprende el arsénico destinadas a una administración oral en pacientes | |
| RU2013121788A (ru) | Ингибиторы репликации вич | |
| JP2017507995A5 (enExample) | ||
| GB0814302D0 (en) | Compounds and methods | |
| RU2019142507A (ru) | Композиции, способы и системы для синтеза и применение визуализирующих средств | |
| JP2005523295A5 (enExample) | ||
| ES2698363T3 (es) | Composiciones de oxprenolol para tratar el cáncer | |
| JP2015516418A5 (enExample) | ||
| JP4779298B2 (ja) | 抗腫瘍剤 | |
| ES3028429T3 (en) | Pharmaceutical capsule composite formulation comprising tadalafil and tamsulosin | |
| JP2014521641A5 (enExample) | ||
| RU2017144574A (ru) | Пероральная композиция целекоксиба для лечения боли | |
| JP5837919B2 (ja) | （ｅ）−４−カルボキシスチリル−４−クロロベンジルスルホンの改善された安定な水性製剤 | |
| JPWO2021007245A5 (enExample) | ||
| JP2019502751A5 (enExample) | ||
| US10874741B2 (en) | Compound to treat Sjogren's syndrome | |
| JP2006524190A5 (enExample) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |